Navigation Links
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Date:9/5/2007

mplex than the patients treated with the bare metal stent.

"The results from ARTS II are excellent for the CYPHER(R) Stent in very complex patients. The ARTS I and II Studies were designed to provide valuable information to help physicians evaluate how to best improve clinical outcomes and increase the quality-of-life of patients with multivessel disease," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. "Their results add to the large body of existing evidence assessing the performance of the CYPHER(R) Stent in a wide range of patient populations."

In the United States, the CYPHER(R) Stent is indicated for de novo lesions less than 30 mm in length in native coronary arteries between 2.5 mm and 3.5 mm in diameter. It does not have an approved indication for patients with multivessel disease, diabetes or blockages located at a bifurcation.

The ARTS II Study is sponsored by Cordis Corporation.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindi
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Genetic Analysis Systems Enter the Clinical Mainstream
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Suisse, October 1, 2014 ... clinique et dans le domaine de l,analyse des ... lancé aujourd,hui une solution de diagnostic in vitro ... une analyse complète de la mucoviscidose dans un ... et de caractériser tous les types de variantes ...
(Date:10/1/2014)... , October 1, 2014 ... Next Generation Sequencing (NGS) data analysis, today launches a ... cystic fibrosis analysis in a single NGS experiment. The ... all types of variants in a single NGS experiment ... it has not been possible to simultaneously analyse all ...
(Date:9/30/2014)... the health and safety of Canadians is our government,s highest priority.  ... tools at its disposal to help ensure that the drugs Canadians ... that end, Health Canada has taken ... of all drug products from three plants in ... Apotex Pharmachem India Pvt Ltd , Apotex Research Private Limited ...
Breaking Medicine Technology:Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2
... Calif., Dec. 6, 2011 A new study ... clinics across the United States witnessed opiate prescriptions for ... 2008.  Dr. Michael Lowenstein, co-medical director for the Waismann ... , warns that this increase signals the gaining popularity ...
... a pioneer in the innovative treatment of extracorporeal ... that the first patient has been enrolled in ... of the company,s photopheresis technology in the treatment ... An estimated 15,000 new patients worldwide are diagnosed ...
Cached Medicine Technology:Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 2Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 3First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease 2First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease 3
(Date:9/30/2014)... measure damaging "brain tsunamis" in injured patients without ... to reality, thanks to pioneering research at the ... research team, led by Jed Hartings, PhD, research ... the UC College of Medicine, has shown that ... brain like tsunami wavescan be measured by the ...
(Date:9/30/2014)... apnea is a potential health risk for millions of Americans, ... the disorder: a "fat" tongue. "This is the first ... tongue of obese patients with obstructive sleep apnea," study senior ... the University of Pennsylvania Medical Center, said in a news ... Oct. 1. Sleep apnea is a common disorder in ...
(Date:9/30/2014)... PROVIDENCE, R.I. [Brown University] Autism is no stranger ... the East African nation is access to clinical services, ... autism diagnostic measure, for example, validated for use in ... small new study, however, researchers at Brown University and ... diagnostic approach that they implemented at two sites in ...
(Date:9/30/2014)... WASHINGTON Legislation passed in 2003 to slow the ... government to treat Medicare patients has had no meaningful ... of researchers in the Journal of Clinical Oncology ... of outpatient chemotherapy to treat colorectal and lung cancers, ... oncologists prescribe those drugs following the implementation of the ...
(Date:9/30/2014)... New York, NY (PRWEB) September 30, 2014 ... and falling demand have hampered growth in the ... Popular diets have caused consumers to moderate their ... growing consumer preferences for premium varieties shrunk the ... bread products. Successful operators proactively responded by introducing ...
Breaking Medicine News(10 mins):Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... space technology is helping doctors diagnose and monitor ... its early stages, before it causes heart attacks ... the country are using ArterioVision software initially developed ... along with a standardized, painless, non-invasive ultrasound examination ...
... J. Fox Foundation for Parkinson's Research announced $710,000 in ... leveraging existing data and patient populations to initially characterize ... that may differ in onset, progression and response to ... of Parkinson's disease -- for patients, researchers and clinicians ...
... of concern as most of them are related to mental ... problems due to which people abstained from work. ... Development (CIPD) on about 30,000 workers revealed that mental illness ... muscle related problems like bad back. ,The study ...
... N.J., Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) ... approved a new indication for REMICADE(R) (infliximab) allowing ... (CD) in pediatric patients aged 6 to 17 ... including a corticosteroid, an immunomodulator and primary nutrition ...
... Annual Meeting of the Society for Vascular Surgery, ... worldwide launch of the Cordis AVIATOR (TM) Plus ... for patients with carotid and or renal artery ... and low profile .014 inch rapid exchange (RX) ...
... Ozzy Osbourne says that getting rid of smoking was more ... and alcohol . ,The former hellraiser, who quit ... he has not gotten hooked to smoking again.,He revealed that ... himself with nicotine patches. ,"They're all a b**ger ...
Cached Medicine News:Health News:NASA Technology Helps Detect and Treat Heart Disease and Strokes 2Health News:NASA Technology Helps Detect and Treat Heart Disease and Strokes 3Health News:Michael J. Fox Foundation Awards $710,000 to Understanding of Parkinson's Disease Subtypes 2Health News:Mental Illness Foremost Reason for Absenteeism 2Health News:Remicade(R) Get Approval for First and Only Biologic Treatment for Pediatric Crohn's Disease 2Health News:New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: